Refine
Year of publication
Document Type
- Article (30491)
- Part of Periodical (11868)
- Book (8231)
- Doctoral Thesis (5585)
- Part of a Book (3869)
- Working Paper (3370)
- Review (2918)
- Contribution to a Periodical (2278)
- Preprint (1809)
- Report (1561)
Language
- German (42680)
- English (28408)
- French (1071)
- Portuguese (843)
- Multiple languages (310)
- Spanish (309)
- Croatian (302)
- Italian (196)
- mis (174)
- Turkish (168)
Keywords
- Deutsch (1082)
- Literatur (862)
- taxonomy (737)
- Deutschland (551)
- Rezension (511)
- new species (438)
- Rezeption (349)
- Frankfurt <Main> / Universität (341)
- Übersetzung (311)
- Geschichte (300)
Institute
- Medizin (7357)
- Präsidium (5082)
- Physik (4114)
- Extern (2742)
- Wirtschaftswissenschaften (2656)
- Gesellschaftswissenschaften (2366)
- Biowissenschaften (2109)
- Biochemie und Chemie (1949)
- Center for Financial Studies (CFS) (1608)
- Informatik (1576)
Einen einzelnen Satz aus der Bibel übersetzen: Dies ist die Aufgabe, an der die Protagonistin von Ingeborg Bachmanns Erzählung Simultan, die Simultandolmetscherin Nadja, scheitert. Der Satz, der auf Italienisch zitiert wird und ins Deutsche übersetzt werden soll, hat es offenbar in sich. Er lautet: "Il miracolo, come sempre, è il risultato della fede e d’una fede audace" – das Wunder ist, wie immer, das Ergebnis des Glaubens und eines kühnen Glaubens. Mit genau diesen Worten übersetzt Nadja den Satz; sie erkennt aber zugleich, dass sie ihn nicht wirklich übersetzen kann. Diese Paradoxie einer Übersetzung des Unübersetzbaren geht mit einer zweiten, intertextuellen Paradoxie einher. Nadja findet nämlich den Satz in einem Buch, das als "Il Vangelo" (das Evangelium) und "bloß die Bibel" bezeichnet wird. Doch der Satz lässt sich dort nicht nachweisen. Die Bachmann-Forschung, einschließlich der Kritischen Ausgabe zum Todesarten-Projekt, bezieht dazu keine Stellung und schenkt so dem Verweis auf die Bibel stillschweigend Glauben. Nur wenige Simultan-Interpretationen fällen das Urteil: Dies ist kein Bibelvers.
The claim of this paper is that embedded definites can, despite the appearances, be accounted for on the uniqueness approach. Far from being a surprise, we argue that the behavior of embedded definites is actually expected once two independent facts are taken into account: the ability of noun phrases to take scope, i.e., to be interpreted in a different place from their syntactic position, and the interaction of presuppositions and scope-taking elements. Specifically, we analyze embedded definites as a case of inverse linking (Gabbay and Moravscik, 1974; May, 1977): the embedded definite takes scope over the embedding one. The presupposition of the embedded definite is weakened as a result of the independently motivated process of intermediate accommodation (Kratzer, 1989; Berman, 1991). In our case, this process transfers the presupposition of the embedding definite into the restrictor of the embedded one.
Like other scope-taking processes, inverse linking is generally taken to be subject to locality constraints: if a syntactic island, such as a finite clause boundary, intervenes in the path of a scope-taking element, then the resulting reading is unavailable or degraded (Rodman, 1976). Since our account views embedded definites as cases of inverse linking, we predict that inserting an island into an embedded definite, all else being equal, should lead to a similar degradation. We report results from an online survey with 800 participants that confirm this prediction.
To overcome poor treatment response of pediatric high-risk acute lymphoblastic leukemia (ALL), novel treatment strategies are required to reactivate programmed cell death in this malignancy. Therefore, we take advantage of using small-molecule antagonists of Inhibitor of apoptosis (IAP) proteins, so called Smac mimetics such as BV6, which are described to overcome apoptosis resistance and thereby sensitize tumor cells for several apoptotic stimuli. To address the question whether redox alterations can sensitize leukemic cells for Smac mimetic-mediated cell death, we interfered with the cellular redox status in different ALL cell lines. Here, we show for the first time that redox alterations, mediated by the glutathione depleting agent Buthioninesulfoximine (BSO), prime ALL cells for BV6-induced apoptosis. Besides ALL cell lines, BV6/BSO cotreatment similarly synergizes in cell death induction in patient-derived primary leukemic samples. In contrast, the combination treatment does not exert any cytotoxicity against peripheral blood lymphocytes (PBLs) or mesenchymal stroma cells (MSCs) from healthy donors, suggesting some tumor selectivity of this treatment. We also identify the underlying molecular mechanism of the novel synergistic drug interaction of BSO and BV6. We demonstrate that both agents act in concert to increase reactive oxygen species (ROS) production, lipid peroxidation and finally apoptotic cell death. Enhanced ROS levels in the combination treatment account for cell death induction, since several ROS scavengers, like NAC, MnTBAP and Trolox attenuate BSO/BV6-induced apoptosis. BSO/BV6-induced ROS can be mainly classified as lipid peroxides, since the vitamin E derivate α-Tocopherol as well as Glutathione peroxidase 4 (GPX4), which both specifically reduce lipid-membrane peroxides, prevent lipid peroxidation, caspase activation and cell death induction. Vice versa, GPX4 knockdown and pharmacological inhibition of GPX4 by RSL3 or Erastin enhance BV6-induced cell death. Importantly, cell death induction critically depends on the formation of a complex consisting of RIP1/FADD/Caspase-8, since all complex components are required for ROS production, lipid peroxidation and cell death induction. Taken together, we demonstrate that BSO and BV6 cooperate to induce ROS production and lipid peroxidation which are eventually required for caspase activation and cell death execution. Collectively, findings of this study indicate that BV6-induced apoptosis is mediated via redox alterations offering promising new treatment strategy to overcome apoptosis resistance in ALL.
Hepatocellular carcinoma (HCC) is the fifth most common malignant tumor and third leading cause of cancer-related death worldwide. Most cases arise as a consequence of underlying liver disease, e.g. developed from chronic hepatitis B or C infectionsalcohol abuse or obesity, and are most often associated with liver cirrhosis. Hypoxiand the hypoxia inducible factors (HIF)-1α and -2α promote tumor progression of HCC, not only affecting tumor cell proliferation and invasion, but also angiogenesis and lymphangiogenesis and thus, increasing the risk of metastasis.
HCC is characterized as one of the most vascularized solid tumors. While HIF-1α and HIF-2α are frequently up-regulated in HCC only HIF-2α is correlated with high patientlethality. HIF-dependent regulation of HCC angiogenesis is controversially discussed.VEGFA, for example, as the most prominent factor inducing tumor angiogenesis represents not only a HIF-1 target, but also a HIF-2 target gene in HCC. This questions whether both isoforms have overlapping functions in regulating the angiogenic switch in HCC.
Besides angiogenesis also tumor-associated lymphangiogenesis significantly influences patient survival in HCC. Lymphatic spread is an important clinical determinant for the prognosis of HCC, but little is known how lymphangiogenesis is controlled in this context. To date, mainly HIF-1α was positively correlated with olymphatic invasion and metastasis in HCC, while a defined role of HIF-2α is missing. Thus, although HIF-1α and HIF-2α are structurally alike and regulate overlapping but not identical sets of target genes, they promote highly divergent outcomes in cancer progression and may even have counteracting roles. The aim of my work was to characterize the specific role of HIF-1α and HIF-2α in the angiogenic switch and lymphangiogenesis induction during HCC development.
Therefore, I created a stable knockdown of HIF-1α and HIF-2α in HepG2 cells and generated cocultures of HepG2 spheroids and embryonic bodies derived from embryonic mouse stem cells as an in vitro tumor model mimicking the cancer microenvironment to analyze which HIF isoform has key regulatory functions in HCC (lymph)angiogenesis. In cocultures with a HIF-2α knockdown angiogenesis was attenuated but lymphangiogenesis increased, while the knockdown of HIF-1α was without effect. Microarray analysis identified plasminogen activator inhibitor 1 (PAI-1)and insulin-like growth factor binding protein 1 (IGFBP1) as HIF-2 target genes.However, prominent angiogenic and lymphangiogenic factors such as VEGFs, PDGFB, ANG and their receptors were not regulated in a HIF-dependent manner. As PAI-1 was linked to angiogenesis in literature and IGF-signaling, which is negatively regulated by IGFBP-1, was correlated with lymphangiogenesis, I decided to investigate their HIF-2α-dependent influence on HCC (lymph)angiogenesis. The knockdown of PAI-1 in HepG2 cells also lowered angiogenesis in PAI-1k/d cocultures similar to the HIF-2α k/d phenotype. PAI-1 as the potent inhibitor of tPA and uPA, both inducing the conversion of plasminogen to plasmin, also inhibits plasmin directly. Therefore, I assumed an increase of plasmin in HIF-2α k/d and PAI-1 k/d cocultures as a result of the reduced PAI-1 levels. Blocking plasmin with aprotinin in HIF-2α k/d cocultures restored angioge nesis, suggesting that HIF-2α increases PAI-1 to lower concentrations of active plasmin, thereby supporting angiogenesis. In further experiments I could exclude PAI-1 to reduce angiogenesis by inducing plasmin-mediated apoptosis of differentiating stem cells in PAI-1 k/d and HIF-2α k/d cocultures, but demonstrated an increase of VEGFA165 degradation in these cocultures, suggesting plasmin-catalyzed proteolysis of VEGF as an additional layer of regulation required to explain the angiogenic phenotype. Besides the pivotal role of PAI-1 in angiogenesis I also investigated its potentialinfluence in lymphangiogenesis. Indeed, the knockdown of PAI-1 reduced lymphaticstructures and implied an important but opposing role in lymphangiogenesis comparedto induced lymphangiogenesis in HIF-2α k/d cocultures. However, blocking plasmin again with aprotinin in HIF-2α k/d cocultures restored lymphangiogenesis to the level of control virus, which indicates a divergent lymphangiogenic role of plasmin in PAI-1 k/d and HIF-2α k/d cocultures, possibly because of other essential pathways masking the lymphangiogenic effects of PAI-1 in HIF-2α k/d cocultures.
HIF-2α resulting in reduced IGFBP1 expression induced the differentiation of stem cells toward a lymphatic cell type and significantly enhanced the assembly of human dermal lymphatic endothelial cells into tubes. These data point the first time to an important impact of HIF-2 in the regulatin of lymphangiogenesis in vitro by inducing IGFBP1 and thus, scavenging IGF-1. Furthermore, matrigel plug assays to investigate the in vivorelevance of these observations confirmed HIF-2α as a crucial factor in the regulation of lymphangiogenesis in vivo
In conclusion, this work provides evidence that HIF-2α is a key regulator of angiogenesis and lymphangiogenesis in HCC by regulating PAI-1 and IGFBP1. HIF-2α positively influences the angiogenic switch via PAI-1 and negatively affects lymphangiogenesis via IGFBP1 expression. Targeting HIF-2α in HCC to reduce tumor angiogenesis should be approached carefully, as it might be overcome by induced lymphangiogenesis and metastasis.
There is a growing debate about complementing the European Monetary Union by a more comprehensive fiscal union. Against this background, this paper emphasizes that there is a trade-off in designing a system of fiscal transfers ("fiscal capacity") in a union between members of different size. A system cannot guarantee symmetric treatment of members and simultaneously ensure a balanced budget. We compute hypothetical transfers for the Eurozone members from 2001 to 2012 to illustrate this trade-off. Interestingly, a symmetric system that treats shocks in small and large countries symmetrically would have produced large budgetary surpluses in 2009, the worst year of the financial crisis.